We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
Read MoreHide Full Article
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported adjusted earnings of $4.06 per share for the first quarter of 2025, missing the Zacks Consensus Estimate of $4.22. Earnings declined 14.7% on a year-over-year basis.
The company reported total revenues of $2.77 billion for the first quarter, which missed the Zacks Consensus Estimate of $2.82 billion. Total revenues rose 3% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe). (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
VRTX’s total revenues comprised cystic fibrosis (“CF”) and other products revenues, as well as other collaboration revenues.
Shares of Vertex have rallied 24.3% so far this year against the industry’s decrease of 2.2%.
Image Source: Zacks Investment Research
VRTX's Q1 Results in Detail
Total revenues rose 9% year over year in the United States to $1.66 billion, while sales outside the United States decreased 5% to $1.11 billion. On the first-quarter conference call, management stated that revenues in ex-U.S. markets were negatively impacted by the availability of an illegal copy product in Russia, where Vertex is experiencing a violation of its intellectual property rights.
The company recorded $10 million of collaboration revenues in the first quarter.
The company’s total product revenues comprise sales of Trikafta/Kaftrio, the newly approved CFTR modulator therapy, Alyftrek (vanza triple) and other product revenues.
Trikafta generated sales worth $2.54 billion, up 2.4% year over year. The product’s sales narrowly missed the Zacks Consensus Estimate of $2.55 billion as well as our model estimate of $2.62 billion.
Alyftrek generated sales worth $53.9 million in the first quarter. Alyftrek, a next-in-class triple combination regimen, was approved by the FDA in December 2024 for treating people with CF aged six years and older. Management is already seeing a steady uptake from all patient groups who are eligible for treatment with Alyftrek.
Revenue from other products decreased 17.4% year over year to $170.8 million.
Other product revenues included $14.2 million in sales of Casgevy, an insignificant amount from the newly approved pain drug, Journavx (suzetrigine) as well as sales of VRTX’s other CF products – Symdeko/Symkevi (marketed as Symkevi in Europe), Orkambi and Kalydeco.
Vertex and partner CRISPR Therapeutics’ (CRSP - Free Report) one-shot gene therapy, Casgevy, was approved for two blood disorders, sickle cell disease and transfusion-dependent beta-thalassemia, in multiple regions in late 2023/early 2024.
Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement with support from CRISPR Therapeutics.
Casgevy sales surged 77.5% on a sequential basis, reflecting strong adoption already.
The FDA approved Vertex’s oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, Journavx, for the treatment of adults with moderate-to-severe acute pain in January 2025.
VRTX's Q1 Cost Discussion
Adjusted research and development (R&D) expenses were up 31.2% year over year to $879 million while adjusted selling, general and administrative (SG&A) expenses increased 22.4% to $333 million in the reported quarter due to higher investment in various ongoing clinical studies and higher expenses to support the commercial launch of Journavx.
During the first quarter, Vertex recorded acquired in-process research and development (AIPR&D) costs of $19.8 million compared with $76.8 million reported in the year-ago quarter.
Adjusted operating income was almost $1.18 billion in the quarter, indicating a decrease of almost 12% year over year.
VRTX's 2025 Guidance
The company raised the lower end of its total revenue guidance for full-year 2025.
Vertex now expects total revenues in the range of $11.85-$12 billion for 2025 compared with the previous expectation of $11.75-$12 billion. The Zacks Consensus Estimate for total revenues is pegged at $11.86 billion for 2025.
The updated guidance reflects the continued growth in CF medicines, including the launch of Alyftrek, the uptake of Casgevy and early contributions from the launch of Journavx.
Combined adjusted R&D, AIPR&D and SG&A expense for 2025 is expected in the band of $4.9-$5 billion. The adjusted tax rate is expected to be in the range of 20.5%-21.5%. Both estimates remain unchanged from the previous expectations.
VRTX's Pipeline Update
Besides acute pain, suzetrigine is also being developed in late-stage studies for the treatment of diabetic peripheral neuropathy and painful lumbosacral radiculopathy.
Vertex has a rapidly advancing mid to late-stage pipeline in other disease areas, like APOL1-mediated kidney diseases, alpha-1 antitrypsin deficiency and cell therapy for type I diabetes (T1D).
A phase II study is evaluating VRTX’s oral formulation of next-gen Nav1.8 inhibitor, VX-993, for the treatment of moderate-to-severe acute pain following bunionectomy surgery. Data from the same is expected in the second half of 2025.
VX-993 is also in phase I development for the intravenous formulation.
The acquisition of Alpine in May 2024 added povetacicept to Vertex’s pipeline. Povetacicept is designed to target two proteins, namely BAFF and APRIL, which are jointly responsible for the cause of multiple serious autoimmune diseases.
The phase III RAINIER study is investigating povetacicept for the treatment of IgA nephropathy. Povetacicept is also being evaluated in two phase II basket studies, one in renal diseases and a second in B cell-mediated diseases. Data from these studies is expected later this year.
Vertex is developing zimislecel in the phase III portion of the ongoing phase I/II/III study for treating patients with T1D with severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia. Enrollment and dosing in this study are expected to be completed later in the second quarter of 2025. Vertex plans to submit regulatory filings seeking approval for zimislecel in T1D in 2026.
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 69 cents to 71 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 38.3%.
ADMA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%.
In the past 60 days, estimates for Immunocore’s loss per share have narrowed from $1.63 to $1.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.83 to $1.68. Year to date, shares of IMCR have gained 3.9%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 31.91%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
Vertex Pharmaceuticals Incorporated (VRTX - Free Report) reported adjusted earnings of $4.06 per share for the first quarter of 2025, missing the Zacks Consensus Estimate of $4.22. Earnings declined 14.7% on a year-over-year basis.
The company reported total revenues of $2.77 billion for the first quarter, which missed the Zacks Consensus Estimate of $2.82 billion. Total revenues rose 3% year over year, primarily driven by higher sales of Trikafta/Kaftrio (marketed as Kaftrio in Europe). (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
VRTX’s total revenues comprised cystic fibrosis (“CF”) and other products revenues, as well as other collaboration revenues.
Shares of Vertex have rallied 24.3% so far this year against the industry’s decrease of 2.2%.
Image Source: Zacks Investment Research
VRTX's Q1 Results in Detail
Total revenues rose 9% year over year in the United States to $1.66 billion, while sales outside the United States decreased 5% to $1.11 billion. On the first-quarter conference call, management stated that revenues in ex-U.S. markets were negatively impacted by the availability of an illegal copy product in Russia, where Vertex is experiencing a violation of its intellectual property rights.
The company recorded $10 million of collaboration revenues in the first quarter.
The company’s total product revenues comprise sales of Trikafta/Kaftrio, the newly approved CFTR modulator therapy, Alyftrek (vanza triple) and other product revenues.
Trikafta generated sales worth $2.54 billion, up 2.4% year over year. The product’s sales narrowly missed the Zacks Consensus Estimate of $2.55 billion as well as our model estimate of $2.62 billion.
Alyftrek generated sales worth $53.9 million in the first quarter. Alyftrek, a next-in-class triple combination regimen, was approved by the FDA in December 2024 for treating people with CF aged six years and older. Management is already seeing a steady uptake from all patient groups who are eligible for treatment with Alyftrek.
Revenue from other products decreased 17.4% year over year to $170.8 million.
Other product revenues included $14.2 million in sales of Casgevy, an insignificant amount from the newly approved pain drug, Journavx (suzetrigine) as well as sales of VRTX’s other CF products – Symdeko/Symkevi (marketed as Symkevi in Europe), Orkambi and Kalydeco.
Vertex and partner CRISPR Therapeutics’ (CRSP - Free Report) one-shot gene therapy, Casgevy, was approved for two blood disorders, sickle cell disease and transfusion-dependent beta-thalassemia, in multiple regions in late 2023/early 2024.
Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement with support from CRISPR Therapeutics.
Casgevy sales surged 77.5% on a sequential basis, reflecting strong adoption already.
The FDA approved Vertex’s oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, Journavx, for the treatment of adults with moderate-to-severe acute pain in January 2025.
VRTX's Q1 Cost Discussion
Adjusted research and development (R&D) expenses were up 31.2% year over year to $879 million while adjusted selling, general and administrative (SG&A) expenses increased 22.4% to $333 million in the reported quarter due to higher investment in various ongoing clinical studies and higher expenses to support the commercial launch of Journavx.
During the first quarter, Vertex recorded acquired in-process research and development (AIPR&D) costs of $19.8 million compared with $76.8 million reported in the year-ago quarter.
Adjusted operating income was almost $1.18 billion in the quarter, indicating a decrease of almost 12% year over year.
VRTX's 2025 Guidance
The company raised the lower end of its total revenue guidance for full-year 2025.
Vertex now expects total revenues in the range of $11.85-$12 billion for 2025 compared with the previous expectation of $11.75-$12 billion. The Zacks Consensus Estimate for total revenues is pegged at $11.86 billion for 2025.
The updated guidance reflects the continued growth in CF medicines, including the launch of Alyftrek, the uptake of Casgevy and early contributions from the launch of Journavx.
Combined adjusted R&D, AIPR&D and SG&A expense for 2025 is expected in the band of $4.9-$5 billion. The adjusted tax rate is expected to be in the range of 20.5%-21.5%. Both estimates remain unchanged from the previous expectations.
VRTX's Pipeline Update
Besides acute pain, suzetrigine is also being developed in late-stage studies for the treatment of diabetic peripheral neuropathy and painful lumbosacral radiculopathy.
Vertex has a rapidly advancing mid to late-stage pipeline in other disease areas, like APOL1-mediated kidney diseases, alpha-1 antitrypsin deficiency and cell therapy for type I diabetes (T1D).
A phase II study is evaluating VRTX’s oral formulation of next-gen Nav1.8 inhibitor, VX-993, for the treatment of moderate-to-severe acute pain following bunionectomy surgery. Data from the same is expected in the second half of 2025.
VX-993 is also in phase I development for the intravenous formulation.
The acquisition of Alpine in May 2024 added povetacicept to Vertex’s pipeline. Povetacicept is designed to target two proteins, namely BAFF and APRIL, which are jointly responsible for the cause of multiple serious autoimmune diseases.
The phase III RAINIER study is investigating povetacicept for the treatment of IgA nephropathy. Povetacicept is also being evaluated in two phase II basket studies, one in renal diseases and a second in B cell-mediated diseases. Data from these studies is expected later this year.
Vertex is developing zimislecel in the phase III portion of the ongoing phase I/II/III study for treating patients with T1D with severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia. Enrollment and dosing in this study are expected to be completed later in the second quarter of 2025. Vertex plans to submit regulatory filings seeking approval for zimislecel in T1D in 2026.
Vertex Pharmaceuticals Incorporated Price, Consensus and EPS Surprise
Vertex Pharmaceuticals Incorporated price-consensus-eps-surprise-chart | Vertex Pharmaceuticals Incorporated Quote
VRTX’s Zacks Rank & Stocks to Consider
Vertex currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are ADMA Biologics Inc. (ADMA - Free Report) and Immunocore Holdings PLC (IMCR - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ADMA Biologics’ earnings per share have increased from 69 cents to 71 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 87 cents to 93 cents. Year to date, shares of ADMA have rallied 38.3%.
ADMA’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 32.80%.
In the past 60 days, estimates for Immunocore’s loss per share have narrowed from $1.63 to $1.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $1.83 to $1.68. Year to date, shares of IMCR have gained 3.9%.
IMCR’s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 31.91%.